Remaining pipeline and cash cushion investor blow as Targacept ends another programme
This article was originally published in Scrip
After Targacept announced the unsuccessful end of its third clinical development programme this year and said for the second time in 2012 that it would lay off employees, the company - which is focused on therapeutics that selectively target neuronal nicotinic receptors (NNRs) to treat nervous system diseases and disorders - experienced a relatively small 11.1% decline in its stock price on 17 September, given its recent string of failures.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.